{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Progenitor+Cells&page=40", "query": { "condition": "Progenitor Cells", "page": 40 }, "page_size": 10 }, "pagination": { "page": 40, "page_size": 10, "total_count": 3272, "total_pages": 328, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Progenitor+Cells&page=41&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Progenitor+Cells&page=39&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T22:25:06.454Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00651937", "title": "Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Primary Amyloidosis" ], "interventions": [ { "name": "Melphalan", "type": "DRUG" }, { "name": "Stem Cell Infusion", "type": "PROCEDURE" }, { "name": "Questionnaires", "type": "BEHAVIORAL" }, { "name": "Granulocyte-colony stimulating factor (G-CSF)", "type": "DRUG" }, { "name": "Apheresis", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 80, "start_date": "2008-03", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2020-01-14", "last_synced_at": "2026-10-19T22:25:06.454Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00651937" }, { "nct_id": "NCT02443077", "title": "Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type", "Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type" ], "interventions": [ { "name": "Autologous Bone Marrow Transplantation", "type": "PROCEDURE" }, { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Pharmacogenomic Study", "type": "OTHER" }, { "name": "Placebo Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2016-10-12", "completion_date": "2026-12-23", "has_results": true, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-19T22:25:06.454Z", "location_count": 280, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Tucson, Arizona + 202 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02443077" }, { "nct_id": "NCT00060372", "title": "Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Childhood Myelodysplastic Syndromes", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Disseminated Neuroblastoma", "Malignant Neoplasm", "Ovarian Choriocarcinoma", "Ovarian Embryonal Carcinoma", "Ovarian Immature Teratoma", "Ovarian Mature Teratoma", "Ovarian Mixed Germ Cell Tumor", "Ovarian Monodermal and Highly Specialized Teratoma", "Ovarian Polyembryoma", "Ovarian Yolk Sac Tumor", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Mantle Cell Lymphoma", "Recurrent Neuroblastoma", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Refractory Chronic Lymphocytic Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage II Ovarian Epithelial Cancer", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Multiple Myeloma", "Stage III Ovarian Epithelial Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Stage IV Ovarian Epithelial Cancer", "Testicular Choriocarcinoma", "Testicular Choriocarcinoma and Embryonal Carcinoma", "Testicular Choriocarcinoma and Seminoma", "Testicular Choriocarcinoma and Teratoma", "Testicular Choriocarcinoma and Yolk Sac Tumor", "Testicular Embryonal Carcinoma", "Testicular Embryonal Carcinoma and Seminoma", "Testicular Embryonal Carcinoma and Teratoma", "Testicular Embryonal Carcinoma and Teratoma With Seminoma", "Testicular Embryonal Carcinoma and Yolk Sac Tumor", "Testicular Embryonal Carcinoma and Yolk Sac Tumor With Seminoma", "Testicular Teratoma", "Testicular Yolk Sac Tumor", "Testicular Yolk Sac Tumor and Teratoma", "Testicular Yolk Sac Tumor and Teratoma With Seminoma" ], "interventions": [ { "name": "ipilimumab", "type": "DRUG" }, { "name": "therapeutic allogeneic lymphocytes", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2003-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-03-27", "last_synced_at": "2026-10-19T22:25:06.454Z", "location_count": 5, "location_summary": "La Jolla, California • Atlanta, Georgia • Boston, Massachusetts", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060372" }, { "nct_id": "NCT01790295", "title": "Ruxolitinib Prior to Transplant in Patients With Myelofibrosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Myelofibrosis", "Post Polycythemia Vera Myelofibrosis", "Post Essential Thrombocythemia Myelofibrosis" ], "interventions": [ { "name": "Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "John Mascarenhas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 21, "start_date": "2013-11", "completion_date": "2017-10-26", "has_results": true, "last_update_posted_date": "2019-03-20", "last_synced_at": "2026-10-19T22:25:06.454Z", "location_count": 6, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Westwood, Kansas + 3 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Westwood", "state": "Kansas" }, { "city": "New York", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01790295" }, { "nct_id": "NCT04365101", "title": "Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Coronavirus", "Coronavirus Infection", "Severe Acute Respiratory Syndrome Coronavirus 2", "Pneumonia", "Pneumonia, Viral", "Lung Diseases", "Respiratory Tract Disease", "Respiratory Tract Infections", "Coronaviridae Infections", "Nidovirales Infections", "RNA Virus Infections", "Virus Disease", "Immunologic Disease", "ARDS", "Immunologic Factors", "Physiological Effects of Drugs", "Antiviral Agents", "Anti-infective Agents", "Analgesics", "Antimetabolites, Antineoplastic" ], "interventions": [ { "name": "CYNK-001", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Celularity Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2020-09-02", "completion_date": "2023-02-15", "has_results": true, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-10-19T22:25:06.454Z", "location_count": 4, "location_summary": "Irvine, California • Morristown, New Jersey • Summit, New Jersey + 1 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Morristown", "state": "New Jersey" }, { "city": "Summit", "state": "New Jersey" }, { "city": "Tacoma", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04365101" }, { "nct_id": "NCT03467919", "title": "The Effect of Micro Fragmented Adipose Tissue (MFAT) on Knee Osteoarthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Osteoarthritis, Knee", "Knee Pain" ], "interventions": [ { "name": "Micro Fragmented Adipose Tissue", "type": "BIOLOGICAL" }, { "name": "Corticosteroid injection", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "35 Years to 75 Years" }, "enrollment_count": 40, "start_date": "2018-04-01", "completion_date": "2024-10-29", "has_results": true, "last_update_posted_date": "2026-01-26", "last_synced_at": "2026-10-19T22:25:06.454Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03467919" }, { "nct_id": "NCT00319657", "title": "Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Immune Tolerance" ], "interventions": [ { "name": "Hematopoietic cell transplantation", "type": "BIOLOGICAL" }, { "name": "Total lymphoid irradiation", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 15, "start_date": "2004-07", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2021-06-18", "last_synced_at": "2026-10-19T22:25:06.454Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00319657" }, { "nct_id": "NCT01427881", "title": "Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Myeloid Leukemia in Remission", "Adult Erythroleukemia (M6a)", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Adult Pure Erythroid Leukemia (M6b)", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Blastic Phase Chronic Myelogenous Leukemia", "Childhood Acute Erythroleukemia (M6)", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Megakaryocytic Leukemia (M7)", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Burkitt Lymphoma", "Childhood Chronic Myelogenous Leukemia", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Myelodysplastic Syndromes", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Chronic Myelomonocytic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "Cutaneous B-cell Non-Hodgkin Lymphoma", "de Novo Myelodysplastic Syndromes", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Noncutaneous Extranodal Lymphoma", "Peripheral T-cell Lymphoma", "Philadelphia Chromosome Negative Chronic Myelogenous Leukemia", "Post-transplant Lymphoproliferative Disorder", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage III Multiple Myeloma", "Testicular Lymphoma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "busulfan", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": 43, "start_date": "2011-09", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2017-05-19", "last_synced_at": "2026-10-19T22:25:06.454Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01427881" }, { "nct_id": "NCT04317781", "title": "Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Blastic Plasmacytoid Dendritic Cell Neoplasm" ], "interventions": [ { "name": "Tagraxofusp-erzs", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 3, "start_date": "2020-03-27", "completion_date": "2023-07-11", "has_results": true, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-10-19T22:25:06.454Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04317781" }, { "nct_id": "NCT02804945", "title": "Mesenchymal Stem Cells (MSCs) for Treatment of Acute Respiratory Distress Syndrome (ARD) in Patients With Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Blood And Marrow Transplantation", "Adult Respiratory Distress Syndrome" ], "interventions": [ { "name": "Mesenchymal Stem Cells (MSCs)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2017-02-24", "completion_date": "2019-06-13", "has_results": false, "last_update_posted_date": "2020-04-10", "last_synced_at": "2026-10-19T22:25:06.454Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02804945" } ] }